Travere Therapeutics announces FDA accelerated approval of Filspari (sparsentan), the first and only non-immunosuppressive therapy for the reduction of proteinuria in IgA nephropathy

Travere Therapeutics

17 February 2023 - Interim results from the ongoing Phase 3 PROTECT head to head trial demonstrated a rapid, sustained and clinically meaningful reduction in proteinuria versus active control, irbesartan.

Travere Therapeutics today announced that the US FDA has granted accelerated approval to Filspari (sparsentan) to reduce proteinuria in adults with primary IgAN at risk of rapid disease progression, generally a urine protein-to-creatinine ratio ≥1.5 g/g.

Read Travere Therapeutics press release

Michael Wonder

Posted by:

Michael Wonder